NCT03275740

Simple Title
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO -CONTROLLED, FIRST-IN-HUMAN TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF PF 06755347 AFTER SINGLE ASCENDING INTRAVENOUS AND SUBCUTANEOUS DOSING IN HEALTHY ADULT MALE PARTICIPANTS AND OPEN-LABEL AFTER SINGLE SUBCUTANEOUS DOSING IN MALE AND FEMALE PARTICIPANTS WITH PERSISTENT OR CHRONIC PRIMARY IMMUNE THROMBOCYTOPENIA

Healthy

Who may participate

Each clinical study has its own guidelines for who may participate, called eligibility criteria. These factors can include your age, sex, overall health, type and stage of disease, and personal treatment history. However, only the research study staff can determine if you qualify to enroll in the study.

Condition

Healthy, Primary Immune Thrombocytopenia, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.
Sex
Male or Female
The sex of people who may participate in a clinical trial (all, female, male). Sex is a person’s classification based on assignment at birth. Eligibility based on sex is distinct from eligibility based on gender.
Age
18 - 55 years
The age a person must be to participate in a clinical trial.
View more eligibility criteria on ClinicalTrials.gov

Study Locations

Study Locations
5 trials found.

Pfizer Clinical Research Unit

Brussels, Belgium, B-1070
Recruiting Get directions

NZCR (New Zealand Clinical Research) OPCO Limited

Christchurch, New Zealand, 8011
Recruiting Get directions

Hospital Universitario La Paz

Madrid, Spain, 28046
Recruiting Get directions

Hospital Universitario Virgen del Rocío

Sevilla, Spain, 41013
Recruiting Get directions

Hammersmith Medicines Research (HMR)

London, United Kingdom, NW10 7EW
Recruiting Get directions